Current section and species complex concepts in Aspergillus: Recommendations for routine daily practice

Annals of the New York Academy of Sciences

Volumn 1273, Issue 1, 2012, Pages 18-24

  Alastruey Izquierdo, Ana ^a   Mellado, Emilia ^a   Cuenca Estrella, Manuel ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Aspergillus; Molecular identification; Resistance

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLOSIS; ASPERGILLUS; MOLECULAR GENETICS; NONHUMAN; TAXONOMY;

EID: 84870912317     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2012.06822.x     Document Type: Article

References (42)

1. Alastruey-Izquierdo, A., I. Cuesta, J. Houbraken, et al 2010. In vitro activity of nine antifungal agents against clinical isolates of Aspergillus calidoustus. Med. Mycol. 48: 97-102.
2. Balajee, S.A., J.L. Gribskov, E. Hanley, et al 2005. Aspergillus lentulus sp. nov., a new sibling species of A. fumigatus. Eukaryot. Cell 4: 625-632.
3. Gilgado, F., J. Cano, J. Gene & J. Guarro 2005. Molecular phylogeny of the Pseudallescheria boydii species complex: proposal of two new species. J. Clin. Microbiol. 43: 4930-4942.
4. Varga, J., J. Houbraken, H.A. Van Der Lee, et al 2008. Aspergillus calidoustus sp. nov., causative agent of human infections previously assigned to Aspergillus ustus. Eukaryot. Cell 7: 630-638.
5. Kontoyiannis, D.P., K.A. Marr, B.J. Park, et al 2010. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin. Infect. Dis. 50: 1091-1100.
6. Lass-Florl, C. 2009. The changing face of epidemiology of invasive fungal disease in Europe. Mycoses 52: 197-205.
7. Taylor, J.W., D.J. Jacobson, S. Kroken, et al 2000. Phylogenetic species recognition and species concepts in fungi. Fungal Genet. Biol. 31: 21-32.
8. Alastruey-Izquierdo, A., K. Hoffmann, G.S. De Hoog, et al 2010. Species recognition and clinical relevance of the zygomycetous genus Lichtheimia (syn. Absidia pro parte, Mycocladus). J. Clin. Microbiol. 48: 2154-2170.
9. O'Donnell, K., D.A. Sutton, M.G. Rinaldi, et al 2009. Novel multilocus sequence typing scheme reveals high genetic diversity of human pathogenic members of the Fusarium incarnatum-F. equiseti and F. chlamydosporum species complexes within the United States. J. Clin. Microbiol. 47: 3851-3861.
10. Balajee, S.A., J.W. Baddley, S.W. Peterson, et al 2009. Aspergillus alabamensis, a new clinically relevant species in the section. Terrei Eukaryot. Cell 8: 713-722.
11. Alvarez, E., J. Cano, A.M. Stchigel, et al 2011. Two new species of Mucor from clinical samples. Med. Mycol. 49: 62-72.
12. Balajee, S.A., A.M. Borman, M.E. Brandt, et al 2009. Sequence-based identification of Aspergillus, Fusarium, and mucorales species in the clinical mycology laboratory: where are we and where should we go from here? J. Clin. Microbiol. 47: 877-884.
13. Samson, R. & J. Varga 2012. Molecular Systematics of Aspergillus and its Teleomorphs. In Aspergillus: Molecular Biology and Genomics M. Machida & K. Gomi, Eds.: 19-40. Caister Academic Press. Wymondham, UK
14. Hachem, R.Y., D.P. Kontoyiannis, M.R. Boktour, et al 2004. Aspergillus terreus: an emerging amphotericin B-resistant opportunistic mold in patients with hematologic malignancies. Cancer 101: 1594-1600.
15. Lass-Florl, C., G. Kofler, G. Kropshofer, et al 1998. In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis. J. Antimicrob. Chemother. 42: 497-502.
16. Hedayati, M.T., A.C. Pasqualotto, P.A. Warn, et al 2007. Aspergillus flavus: human pathogen, allergen and mycotoxin producer. Microbiology 153: 1677-1692.
17. Balajee, S.A., J. Gribskov, M. Brandt, et al 2005. Mistaken identity: Neosartorya pseudofischeri and its anamorph masquerading as Aspergillus fumigatus. J. Clin. Microbiol. 43: 5996-5999.
18. Hong, S.B., S.J. Go, H.D. Shin, et al 2005. Polyphasic taxonomy of Aspergillus fumigatus and related species. Mycologia 97: 1316-1329.
19. Alcazar-Fuoli, L., E. Mellado, A. Alastruey-Izquierdo, et al 2008. Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification. Antimicrob. Agents Chemother. 52: 1244-1251.
20. Hendrickx, M., H. Beguin & M. Detandt 2012. Genetic re-identification and antifungal susceptibility testing of Aspergillus section Nigri strains of the BCCM/IHEM collection. Mycoses 55: 148-155.
21. Howard, S.J., E. Harrison, P. Bowyer, et al 2011. Cryptic species and azole resistance in the Aspergillus niger complex. Antimicrob. Agents Chemother. 55: 4802-4809.
22. Balajee, S.A., R. Kano, J.W. Baddley, et al 2009. Molecular identification of Aspergillus species collected for the Transplant-Associated Infection Surveillance Network. J. Clin. Microbiol. 47: 3138-3141.
23. Gerber, J., J. Chomicki, J.W. Brandsberg, et al 1973. Pulmonary aspergillosis caused by Aspergillus fischeri var. spinosus: report of a case and value of serologic studies. Am. J. Clin. Pathol. 60: 861-866.
24. Guarro, J., E.G. Kallas, P. Godoy, et al 2002. Cerebral aspergillosis caused by Neosartorya hiratsukae. Brazil Emerg. Infect. Dis. 8: 989-991.
25. Jarv, H., J. Lehtmaa, R.C. Summerbell, et al 2004. Isolation of Neosartorya pseudofischeri from blood: first hint of pulmonary Aspergillosis. J. Clin. Microbiol. 42: 925-928.
26. Rodriguez-Tudela, J.L., L. Alcazar-Fuoli, E. Mellado, et al 2008. Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus. Antimicrob. Agents Chemother. 52: 2468-2472.
27. AFST EUCAST. 2012. Clinical breakpoints - fungi (v 4.1). http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/AFST/Antifungal_breakpoints_v_4.1.pdf.
28. Lass-Florl, C., A. Alastruey-Izquierdo, M. Cuenca-Estrella, et al 2009. In vitro activities of various antifungal drugs against Aspergillus terreus: global assessment using the methodology of the European committee on antimicrobial susceptibility testing. Antimicrob. Agents Chemother. 53: 794-795.
29. Lass-Florl, C., K. Griff, A. Mayr, et al 2005. Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience. Br. J. Haematol. 131: 201-207.
30. Balajee, S.A., M.D. Lindsley, N. Iqbal, et al 2007. Nonsporulating clinical isolate identified as Petromyces alliaceus (anamorph Aspergillus alliaceus) by morphological and sequence-based methods. J. Clin. Microbiol. 45: 2701-2703.
31. Ozhak-Baysan, B., A. Alastruey-Izquierdo, R. Saba, et al 2010. Aspergillus alliaceus and Aspergillus flavus co-infection in an acute myeloid leukemia patient. Med. Mycol. 48: 995-999.
32. Baddley, J.W., K.A. Marr, D.R. Andes, et al 2009. Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the Transplant-Associated Infection Surveillance Network. J. Clin. Microbiol. 47: 3271-3275.
33. Auberger, J., C. Lass-Florl, J. Clausen, et al 2008. First case of breakthrough pulmonary Aspergillus niveus infection in a patient after allogeneic hematopoietic stem cell transplantation. Diagn. Microbiol. Infect. Dis. 62: 336-339.
34. Escribano, P., T. Pelaez, S. Recio, et al 2012. Characterization of clinical strains of Aspergillus terreus complex: molecular identification and antifungal susceptibility to azoles and amphotericin. B Clin. Microbiol. Infect. 18: E24-E26.
35. Mellado, E., T.M. Diaz-Guerra, M. Cuenca-Estrella & J.L. Rodriguez-Tudela 2001. Identification of two different 14-alpha sterol demethylase-related genes (cyp51A and cyp51B) in Aspergillus fumigatus and other Aspergillus species. J. Clin. Microbiol. 39: 2431-2438.
36. Mellado, E., G. Garcia-Effron, L. Alcazar-Fuoli, et al 2004. Substitutions at methionine 220 in the 14alpha-sterol demethylase (Cyp51A) of Aspergillus fumigatus are responsible for resistance in vitro to azole antifungal drugs. Antimicrob. Agents Chemother. 48: 2747-2750.
37. Mellado, E., G. Garcia-Effron, L. Alcazar-Fuoli, et al 2007. A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob. Agents Chemother. 51: 1897-1904.
38. Mellado, E., L. Alcazar-Fuoli, M. Cuenca-Estrella & J.L. Rodriguez-Tudela 2011. Role of Aspergillus lentulus 14-alpha sterol demethylase (Cyp51A) in azole drug susceptibility. Antimicrob. Agents Chemother. 55: 5459-5468.
39. Howard, S.J., D. Cerar, M.J. Anderson, et al 2009. Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg. Infect. Dis. 15: 1068-1076.
40. Snelders, E., H.A. Van Der Lee, J. Kuijpers, et al 2008. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med. 5: e219.
41. Alanio, A., J.L. Beretti, B. Dauphin, et al 2011. Matrix-assisted laser desorption ionization time-of-flight mass spectrometry for fast and accurate identification of clinically relevant Aspergillus species. Clin. Microbiol. Infect. 17: 750-755.
42. Etienne, K.A., L. Gade, S.R. Lockhart, et al 2009. Screening of a large global Aspergillus fumigatus species complex collection by using a species-specific microsphere-based Luminex assay. J. Clin. Microbiol. 47: 4171-4172.